MAPK14 and breast carcinoma: According to Maiti et al. (2017), treatment of PF-543 (up to 10 μM) attenuated EGF-mediated cell growth, survival and migration in metastatic breast cancer cells via inhibition of AKT, ERK, and p38 MAPK pathways (Maiti et al., 2017).